{"nctId":"NCT00630032","briefTitle":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","startDateStruct":{"date":"2007-09","type":"ACTUAL"},"conditions":["Breast Cancer"],"count":762,"armGroups":[{"label":"Docetaxel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cyclophosphamide","Drug: Docetaxel","Drug: epirubicin hydrochloride","Drug: fluorouracil"]},{"label":"Ixabepilone","type":"EXPERIMENTAL","interventionNames":["Drug: cyclophosphamide","Drug: epirubicin hydrochloride","Drug: fluorouracil","Drug: ixabepilone"]}],"interventions":[{"name":"cyclophosphamide","otherNames":[]},{"name":"Docetaxel","otherNames":[]},{"name":"epirubicin hydrochloride","otherNames":[]},{"name":"fluorouracil","otherNames":[]},{"name":"ixabepilone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\nInclusion criteria:\n\n* Histologically proven invasive unilateral breast cancer (regardless of the type)\n\n  * Initial clinical condition compatible with complete initial resection\n  * No residual macro or microscopic tumor after surgical excision\n* Node-positive disease (i.e., positive sentinel node or positive axillary clearance) (N+) or node-negative disease (-) meeting the following criteria :\n\n  * Stage II or III disease\n  * pT \\>20 mm (T1-4)\n* Patients must meet 1 of the following hormone-receptor criteria:\n\n  * Node-positive patients: triple-negative\\* tumor (HER2 negative, estrogen-receptor \\[ER\\] negative, and progesterone receptor \\[PR\\] negative) OR double-negative (HER2 negative, PR negative, and ER+)\n  * Node-negative patients: triple-negative\\* tumor only\n* NOTE: \\*Hormone-receptor negativity is defined as ER \\<10% and PR \\<10% by IHC and HER2 negativity is defined as IHC 0-1+ OR IHC 2+ and FISH or CISH negative\n* Must be able to begin chemotherapy no later than day 49 after the initial surgery\n\nExclusion criteria:\n\n* Clinically or radiologically detectable metastases (M0)\n* Bilateral breast cancer or contralateral ductal carcinoma in situ\n* Any metastatic impairment, including homolateral subclavicular node involvement, regardless of its type\n* Any tumor ≥T4a (cutaneous invasion, deep adherence, inflammatory breast cancer)\n* HER 2 overexpression defined as IHC 3+ OR IHC 2+ and FISH or CISH positive\n* Any clinically or radiologically suspect and non-explored damage to the contralateral breast\n\nPATIENT CHARACTERISTICS:\n\nInclusion criteria:\n\n* Female\n* Pre- or postmenopausal\n* ECOG performance status 0-1\n* Peripheral neuropathy ≤grade 1\n* Neutrophil count ≥2,000/mm³\n* Platelet count ≥100,000/mm³\n* Hemoglobin \\>9 g/dL\n* AST and ALT ≤1.5 times upper limit of normal (ULN)\n* Alkaline phosphatase ≤2.5 times ULN\n* Total bilirubin ≤1.0 times ULN\n* Serum creatinine ≤1.5 times ULN\n* LVEF ≥50% by MUGA scan or echocardiography\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for up to 8 weeks after completion of study treatment\n\nExclusion criteria:\n\n* Previous cancer (except cutaneous baso-cellular epithelioma or uterine peripheral epithelioma) in the preceding 5 years, including invasive contralateral breast cancer\n* Patients with any other concurrent severe and/or uncontrolled medical disease or infection that could compromise participation in the study\n* Clinically significant cardiovascular disease within the past 6 months including any of the following:\n\n  * Unstable angina\n  * Congestive heart failure\n  * Uncontrolled hypertension (i.e., blood pressure \\>150/90 mm Hg)\n  * Myocardial infarction\n  * Cerebral vascular accidents\n* Known prior severe hypersensitivity reactions to agents containing Cremophor EL\n* Patients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule\n* Patients deprived of liberty or placed under the authority of a tutor\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 2 weeks since prior minor surgery (excluding breast biopsy) and adequately recovered\n* At least 3 weeks since prior major surgery and adequately recovered\n* No prior chemotherapy, hormonal therapy, or radiotherapy\n* More than 72 hours since prior and no concurrent treatment with any of the following strong inhibitors of CYP3A4:\n\n  * Amiodarone\n  * Clarithromycin\n  * Amprenavir\n  * Delavirdine\n  * Voriconazole\n  * Erythromycin\n  * Fluconazole\n  * Itraconazole\n  * Ketoconazole\n  * Indinavir\n  * Nelfinavir\n  * Ritonavir\n  * Saquinavir\n* No concurrent participation in another therapeutic trial involving an experimental drug","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Disease-free Survival (DFS)","description":"DFS is defined as the interval between the date of randomization and the date of breast cancer relapse (local, regional or distant) or the date of invasive contralateral breast cancer or death from any cause, whichever occurs first","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.97","spread":null},{"groupId":"OG001","value":"83.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Disease-free Survival Events for Triple-negative Subgroup","description":"DFS is defined as the interval between the date of randomization and the date of breast cancer relapse (local, regional or distant) or the date of invasive contralateral breast cancer or death from any cause, whichever occurs first in participants with triple negative breast cancer only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Disease-free Survival Events for ER+/PR-/HER2- Subgroup","description":"DFS is defined as the interval between the date of randomization and the date of breast cancer relapse (local, regional or distant) or the date of invasive contralateral breast cancer or death from any cause, whichever occurs first in participants with ER+/PR-/HER2- breast cancer only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Distant Metastasis-free Survival Events for the Whole Population","description":"The distant metastases-free survival is the length of time during and after the treatment for cancer that a patient is still alive and the cancer has not spread to other parts of the body.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Event-free Survival","description":"The Event-free Survival is defined as the interval between the date of randomization and the date of breast cancer relapse (local, regional or distant) or the date of invasive contralateral breast cancer or the date of second neoplasia, or the date of death from any cause, whichever occurs first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.46","spread":null},{"groupId":"OG001","value":"81.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"The overall survival is the length of time from randomization that patients enrolled in the study are still alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.00","spread":null},{"groupId":"OG001","value":"87.60","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":207,"n":398},"commonTop":["neutropenia","Alopecia","Nausea","Anemia","Mucitis"]}}}